Browse Category

Financial Forecasts News 20 December 2025

Hecla Mining (HL) Stock News, Forecasts and Analysis for Dec. 20, 2025: Silver Record Highs, S&P MidCap 400 Addition, and What Comes Next

Hecla Mining (HL) Stock News, Forecasts and Analysis for Dec. 20, 2025: Silver Record Highs, S&P MidCap 400 Addition, and What Comes Next

Hecla Mining Company stock (NYSE: HL) is ending 2025 in the spotlight—riding a historic surge in silver prices, fresh company catalysts in Nevada, and a looming index event that could reshape near-term trading flows. As of Dec. 20, 2025 (with the latest trade reflecting Friday’s session), HL is around $19.67 after a volatile day that pushed above $20.50. StockInvest The move caps a remarkable year for the silver-miner complex—and Hecla’s run has been among the most dramatic, with the stock recently printing a new 52‑week high around $20.2 and multiple reports pegging its 2025 gain near ~290%. Investing.com Below is
Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Dec. 20, 2025 — Intuit Inc. (NASDAQ: INTU) enters the weekend with investors balancing a fresh fintech headline—Intuit’s newly announced USDC stablecoin partnership with Circle—against the familiar seasonal catalyst that often defines the stock’s narrative: TurboTax demand heading into the 2026 filing season (tax year 2025 returns filed in early 2026). Intuit Inc.+1 With U.S. markets closed on Saturday, the latest available pricing reflects Friday’s session: INTU closed at $671.30 on Dec. 19, capping a choppy week that saw the stock dip early and rebound into the close. StockAnalysis Below is a comprehensive, publication-ready breakdown of the latest INTU stock
IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

International Business Machines Corporation (NYSE: IBM) enters the final stretch of 2025 with its stock consolidating near the $300 level—an area that has become a focal point for both bulls betting on IBM’s “AI + hybrid cloud” strategy and skeptics warning that the company’s acquisition push could strain the balance sheet. IBM stock last closed at $300.98 on Friday, Dec. 19, 2025, up about 0.18% on the day. With U.S. markets closed on Saturday, Dec. 20, that close is the latest reference point for investors tracking the name into year-end. StockAnalysis What’s driving the debate right now is a tight
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated (NASDAQ: INSM) is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close (the last U.S. trading session before today’s Saturday), Insmed shares finished at $174.84, up about 5% on the day—recovering some ground after Thursday’s steep drop. The catalyst remains the same: Insmed disclosed that its Phase 2b BiRCh study of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP)missed both primary and secondary efficacy endpoints, prompting the company to discontinue that indication. At
Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

December 20, 2025 Texas Instruments Incorporated (NASDAQ: TXN) heads into the weekend at the center of two narratives that rarely collide so neatly: a major U.S. manufacturing milestone and a fresh wave of Wall Street debate about what that investment means for margins, cash flow, and share performance in the next semiconductor cycle. TXN last closed at $176.29 (Dec. 19, 2025), with trading in recent sessions reflecting investor tug-of-war between long-term capacity advantages and short-term profitability concerns. StockAnalysis Below is a full roundup of the current news, forecasts, and analyses relevant to Texas Instruments stock as of 20.12.2025, plus the
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as the company’s main growth engine. Nasdaq+1 Below is a comprehensive roundup of the latest ALNY stock news, forecasts, and market-moving analysis available as of 20.12.2025, plus what to watch next. ALNY stock today: where Alnylam shares stand on Dec. 20, 2025 U.S. markets are closed on Saturday, so the most recent official pricing is from Friday’s session (Dec. 19, 2025).
Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

December 20, 2025 — Salesforce, Inc. (NYSE: CRM) stock is heading into the final stretch of 2025 at the center of a debate investors know well: is this a beaten-down software leader becoming a bargain again, or a “value trap” in a market that’s rewarding AI infrastructure over traditional SaaS? MarketWatch On price action, Salesforce shares last traded around $259.91, after closing Friday, Dec. 19, 2025 at $259.91, up 0.80% on the day, with roughly 20.7 million shares traded. Investing.com What’s driving attention this weekend isn’t a single headline—it’s the convergence of AI commercialization, fresh M&A, and renewed analyst conviction
CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave, Inc. (NASDAQ: CRWV) ends the week back in the spotlight after a sharp Friday rebound that partially reversed a bruising late-2025 selloff. As of the Dec. 19, 2025 close (the last trading session ahead of Dec. 20), CoreWeave shares finished around $83, up roughly 22% on the day, according to MarketBeat’s end-of-day quote. MarketBeat The catalyst wasn’t a single headline—it was a “stack” of market-moving signals that hit within roughly 24–48 hours: That rebound arrives after weeks of volatile trading tied to a broader market debate: whether the AI infrastructure buildout is a durable, cash-generating megatrend—or the early innings
Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston Holdings, Inc. (NYSE: LW) is back in the market’s spotlight this weekend—and not because investors suddenly stopped liking French fries. After reporting second-quarter fiscal 2026 results that beat Wall Street expectations on revenue and adjusted earnings, Lamb Weston shares still fell sharply as investors zeroed in on what management said comes next: continued discounting, unfavorable price/mix, and higher international manufacturing costs that could keep profitability under pressure into the back half of the year. Barron’s+2Reuters+2 Below is what actually happened, what the company guided for fiscal 2026, and how analysts and market watchers are framing the bull case
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest trading data available, IRON was around $80.04, down roughly 11.5% versus the prior close, after trading as high as $94.60 and as low as $71.46 on heavy volume (about 4.22 million shares). The immediate trigger: a report-driven debate about the FDA’s new fast-track voucher process and whether Disc’s lead drug candidate, bitopertin, remains on the clean, accelerated path bulls were
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company (NYSE: LLY) is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 (Dec. 19) after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in cash, valuing the deal at approximately $4.8 billion. BioMarin says the acquisition adds two marketed, growing therapies—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease)—plus U.S. rights to DMX-200 (a Phase 3 kidney-disease asset), while also resolving a key piece
1 15 16 17 18 19 68

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop